News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...

Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is ...

The F8 formulation is 8 times more concentrated than Egrifta and 2 times more concentrated than the current F4 formulation, Egrifta SV.

A study funded by the National Institutes of Health that would test if an antibiotic can prevent sexually transmitted ...

The World Health Organization (WHO) has issued a grave warning about an imminent HIV drug shortage in several countries ...

Quebec is the first province to publicly cover costs of long-acting injectable HIV prevention medication Apretude. Experts ...

Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...

A dissolvable oral dispersible film of dolutegravir could transform treatment ANALYSIS | MELODY CHIRONDA | In the fight ...

Shares of Theratechnologies jumped after the company received Food and Drug Administration approval for Egrifta WR, its treatment for excess abdominal fat in adults with HIV and lipodystrophy.

New, improved formulation set to replace EGRIFTA SV® MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a ...

Feb. 18, 2025 — Viruses, like those that cause COVID-19 or HIV, are formidable opponents once they invade our bodies. Antiviral treatments strive to block a virus or halt its replication.